<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="in this study due to their indispensable nature in the" exact="viral" post="life cycle. 3CLpro is a cysteine protease responsible for"/>
 <result pre="ribose 2â€²-O position of the first and second nucleotide of" exact="viral" post="mRNA, which sequesters it from the host immune system."/>
 <result pre="etÂ al., 2020). Even though the majority of human coronavirus" exact="infections" post="are mild, the epidemics of two betacoronaviruses (Î²CoV), namely"/>
 <result pre="infections are mild, the epidemics of two betacoronaviruses (Î²CoV), namely" exact="Severe" post="Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory"/>
 <result pre="are mild, the epidemics of two betacoronaviruses (Î²CoV), namely Severe" exact="Acute" post="Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome"/>
 <result pre="mild, the epidemics of two betacoronaviruses (Î²CoV), namely Severe Acute" exact="Respiratory" post="Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus"/>
 <result pre="the epidemics of two betacoronaviruses (Î²CoV), namely Severe Acute Respiratory" exact="Syndrome" post="coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV),"/>
 <result pre="namely Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East" exact="Respiratory" post="Syndrome coronavirus (MERS-CoV), has caused more than 10,000 cumulative"/>
 <result pre="Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory" exact="Syndrome" post="coronavirus (MERS-CoV), has caused more than 10,000 cumulative cases"/>
 <result pre="2019, several local health facilities reported groups of patients with" exact="pneumonia" post="of unknown cause, and they were found to be"/>
 <result pre="a novel human-infecting coronavirus (Huang etÂ al., 2020), officially named" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (World Health Organization,"/>
 <result pre="novel human-infecting coronavirus (Huang etÂ al., 2020), officially named Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) (World Health Organization, 2020a)."/>
 <result pre="human-infecting coronavirus (Huang etÂ al., 2020), officially named Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) (World Health Organization, 2020a). Also,"/>
 <result pre="coronavirus (Huang etÂ al., 2020), officially named Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) (World Health Organization, 2020a). Also, the"/>
 <result pre="Also, the World Health Organisation (WHO) has officially named the" exact="disease" post="caused by SARS-CoV-2 as coronavirus disease 2019 (COVID-19) (World"/>
 <result pre="has officially named the disease caused by SARS-CoV-2 as coronavirus" exact="disease" post="2019 (COVID-19) (World Health Organization, 2020a). As of 29"/>
 <result pre="Concern (World Health Organization, 2020e). According to the Centers for" exact="Disease" post="Control and Prevention (CDC) and the WHO, the global"/>
 <result pre="varies significantly with the age of the patients (Centers for" exact="Disease" post="Control and Prevention, 2020). In order to control the"/>
 <result pre="Coronavirus replicase polyprotein. This protease plays a central role in" exact="viral" post="replication and transcription functions through extensive proteolysis of two"/>
 <result pre="principal drug target for SARS-CoV-2. Another crucial protein responsible for" exact="viral" post="replication and expression in host cells is non-structural protein"/>
 <result pre="host cells is non-structural protein 16 (nsp16) or 2â€²-OMTase. Most" exact="viral" post="mRNAs possess a 5â€²-terminal cap structure (m7GpppN) which is"/>
 <result pre="al., 2010). Nsp 16 encodes the 2â€²-OMTase which provides the" exact="viral" post="mRNA with the ability to camouflage and obscure itself"/>
 <result pre="of the host immune response which is essential for successful" exact="viral infection" post="(Menachery etÂ al., 2014). This protein can, therefore, act"/>
 <result pre="the host immune response which is essential for successful viral" exact="infection" post="(Menachery etÂ al., 2014). This protein can, therefore, act"/>
 <result pre="the drugs, their estimated inhibition constant (Ki), Root Mean Square" exact="Deviation" post="(RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration"/>
 <result pre="with the user template option. Template structures were selected from" exact="Protein" post="BLAST (Camacho etÂ al., 2009) against Protein Data Bank"/>
 <result pre="were selected from Protein BLAST (Camacho etÂ al., 2009) against" exact="Protein" post="Data Bank (PDB) (Berman etÂ al., 2000) based on"/>
 <result pre="was utilised for all of the docking calculations. In PyRx," exact="blind" post="docking with the exhaustiveness 32 option was used to"/>
 <result pre="and temperature (NVT). Various structural parameters, like Root Mean Square" exact="Deviation" post="(RMSD), Root Mean Square Fluctuations (RMSF), Radius of Gyration"/>
 <result pre="results, we used the user-defined template option present in SWISS-MODEL." exact="Protein" post="BLAST (Camacho etÂ al., 2009) results were taken into"/>
 <result pre="performed for a period of 100â€‰ns. 3.4.1. Root Mean Square" exact="Deviation" post="analysis RMSD is essential to quantify the structural stability"/>
 <result pre="complex (Red) and 3CLpro-Paritaprevir complex (turquoise). (a) Root Mean Square" exact="Deviation" post="(RMSD), (b) Root Mean Square Fluctuation (RMSF), (c) Radius"/>
 <result pre="around 60â€‰ns, but apart from that, the protein was quite" exact="stable" post="until the end of the simulation cycle. The 2â€²-OMTase-Dolutegravir"/>
 <result pre="(Orange) and 2â€²-OMTase-Dolutegravir complex (Dark Green). (a) Root Mean Square" exact="Deviation" post="(RMSD), (b) Root Mean Square Fluctuation (RMSF), (c) Radius"/>
 <result pre="0.184â€‰nm, respectively. Additionally, the majority of the protein residues were" exact="stable" post="with RMSF values smaller than 0.3â€‰nm. Also, the catalytic"/>
 <result pre="Cys145) participating in interactions with the drug molecules remained highly" exact="stable" post="throughout the MD simulation. In the case of 2â€²-OMTase,"/>
 <result pre="the conserved K-D-K-E (Lys-46, Asp-130, Lys-170 and Glu-203) remained remarkably" exact="stable" post="throughout the MD simulation. 3.4.3. Radius of gyration (Rg)"/>
 <result pre="the conformational shifts that resulted from the changes in the" exact="secondary" post="structures of protein during the MD simulation. In the"/>
 <result pre="as the protein-drug complexes, attained stability at 30â€‰ns and remained" exact="stable" post="until the end (see Figure 6c). The average Rg"/>
 <result pre="results suggested that both of the proteins-drug complexes were impressively" exact="stable" post="after the binding of drug molecules to their active"/>
 <result pre="of unbound proteins as well as the protein-drug complexes using" exact="Essential" post="Dynamics (ED) approach. ED analyses the combined fluctuations of"/>
 <result pre="131.03 3.4.7. Comparative analysis of pre and post MD simulation" exact="Structural" post="superposition before and after the MD simulation of drug-free"/>
 <result pre="simulation of 3CLpro-Raltegravir complex and 3CLpro-Paritaprevir complex was reliable and" exact="stable" post="with the values of 2.15â€‰Ã… and 2.47â€‰Ã…, respectively (see"/>
 <result pre="of 2.15â€‰Ã… and 2.47â€‰Ã…, respectively (see Figure 11). Figure 11." exact="Structural" post="superimposition of the initial and MD simulated free 3CLpro,"/>
 <result pre="and MD simulated free 3CLpro, 3CLpro-Raltegravir complex and 3CLpro-Paritaprevir complex." exact="Structural" post="superposition of pre and post MD simulation of drug-free"/>
 <result pre="simulation of 2â€²-OMTase-Dolutegravir complex and 2â€²-OMTase-Bictegravir complex was reliable and" exact="stable" post="with the values of 1.767â€‰Ã… and 2.568â€‰Ã…, respectively (see"/>
 <result pre="of 1.767â€‰Ã… and 2.568â€‰Ã…, respectively (see Figure 12). Figure 12." exact="Structural" post="superimposition of the initial and MD simulated free 2â€²-OMTase,"/>
 <result pre="2016; Sulkowski etÂ al., 2015), is being used to treat" exact="chronic" post="Hepatitis C Virus (HCV) infections. It suppresses viral replication"/>
 <result pre="Sulkowski etÂ al., 2015), is being used to treat chronic" exact="Hepatitis" post="C Virus (HCV) infections. It suppresses viral replication by"/>
 <result pre="to treat chronic Hepatitis C Virus (HCV) infections. It suppresses" exact="viral" post="replication by inhibiting the non-structural 3/4â€‰A protease of HCV"/>
 <result pre="(2019). Structure based in-silico study on UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase (MurE) from" exact="Acinetobacter" post="baumannii as a drug target against nosocomial infections. Informatics"/>
 <result pre="ligase (MurE) from Acinetobacter baumannii as a drug target against" exact="nosocomial infections." post="Informatics in Medicine Unlocked, 16, 100216. doi:10.1016/j.imu.2019.100216 BenkertP., BiasiniM.,"/>
 <result pre="BhatT. N., WeissigH., ShindyalovI. N., &amp;amp; BourneP. E. (2000). The" exact="Protein" post="Data Bank. Nucleic Acids Research, 28(1), 235â€&quot;242. doi:10.1093/nar/28.1.23510592235 BordoliL.,"/>
 <result pre="235â€&quot;242. doi:10.1093/nar/28.1.23510592235 BordoliL., KieferF., ArnoldK., BenkertP., BatteyJ., &amp;amp; SchwedeT. (2009)." exact="Protein" post="structure homology modeling using SWISS-MODEL workspace. Nature Protocols, 4(1),"/>
 <result pre="&amp;amp; MartinP. (2014). New antiviral agents for the treatment of" exact="hepatitis" post="C: ABT-450. Expert Opinion on Pharmacotherapy, 15(5), 711â€&quot;716. doi:10.1517/14656566.2014.88911624517400"/>
 <result pre="Expert Opinion on Pharmacotherapy, 15(5), 711â€&quot;716. doi:10.1517/14656566.2014.88911624517400 collab: Centers for" exact="Disease" post="Control and Prevention. (2020). Severe outcomes among patients with"/>
 <result pre="711â€&quot;716. doi:10.1517/14656566.2014.88911624517400 collab: Centers for Disease Control and Prevention. (2020)." exact="Severe" post="outcomes among patients with coronavirus disease 2019 (COVID-19) â€&quot;"/>
 <result pre="Control and Prevention. (2020). Severe outcomes among patients with coronavirus" exact="disease" post="2019 (COVID-19) â€&quot; United States, February 12â€&quot;March 16, 2020."/>
 <result pre="(1993). Verification of protein structures: Patterns of nonbonded atomic interactions." exact="Protein" post="Science, 2(9), 1511â€&quot;1519. doi:10.1002/pro.55600209168401235 de WildeA. H., SnijderE. J.,"/>
 <result pre="virologic response of 100% in HCV genotype 1b patients with" exact="cirrhosis" post="receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. Journal of Hepatology,"/>
 <result pre="A., JabÅ‚oÅ&quot;skaJ., PravdaL., VaÅ™ekovÃ¡R. S., &amp;amp; ThorntonJ. M. (2018). PDBsum:" exact="Structural" post="summaries of PDB entries. Protein Science., 27(1), 129â€&quot;134. doi:10.1002/pro.328928875543"/>
 <result pre="&amp;amp; ThorntonJ. M. (2018). PDBsum: Structural summaries of PDB entries." exact="Protein" post="Science., 27(1), 129â€&quot;134. doi:10.1002/pro.328928875543 LaskowskiR. A., MacArthurM. W., MossD."/>
 <result pre="mapping of the RNA cap 2â€™-O-methyltransferase activation interface between severe" exact="acute" post="respiratory syndrome coronavirus nsp10 and nsp16. Journal of Biological"/>
 <result pre="of the RNA cap 2â€™-O-methyltransferase activation interface between severe acute" exact="respiratory" post="syndrome coronavirus nsp10 and nsp16. Journal of Biological Chemistry,"/>
 <result pre="the RNA cap 2â€™-O-methyltransferase activation interface between severe acute respiratory" exact="syndrome" post="coronavirus nsp10 and nsp16. Journal of Biological Chemistry, 285(43),"/>
 <result pre="profiles. Nature, 356(6364), 83â€&quot;85. doi:10.1038/356083a01538787 MadhavN., OppenheimB., &amp;amp; GallivanM. (2017)." exact="Disease" post="control priorities: Improving health and reducing poverty (3rd ed)."/>
 <result pre="native mass spectrometry and molecular dynamics simulations. Current Opinion in" exact="Structural" post="Biology, 54, 50â€&quot;58. doi:10.1016/j.sbi.2018.12.01130743182 MarkowitzM., NguyenB.-Y., GotuzzoE., MendoF., RatanasuwanW.,"/>
 <result pre="infection: Results of a 48-week controlled study. JAIDS Journal of" exact="Acquired" post="Immune Deficiency Syndromes, 46(2), 125â€&quot;133. doi:10.1097/QAI.0b013e318157131c17721395 MenacheryV. D., DebbinkK.,"/>
 <result pre="of a 48-week controlled study. JAIDS Journal of Acquired Immune" exact="Deficiency Syndromes," post="46(2), 125â€&quot;133. doi:10.1097/QAI.0b013e318157131c17721395 MenacheryV. D., DebbinkK., &amp;amp; BaricR. S."/>
 <result pre="G., &amp;amp; BaricR. S. (2014). Attenuation and restoration of severe" exact="acute" post="respiratory syndrome coronavirus mutant lacking 2â€™-o-methyltransferase activity. Journal of"/>
 <result pre="&amp;amp; BaricR. S. (2014). Attenuation and restoration of severe acute" exact="respiratory" post="syndrome coronavirus mutant lacking 2â€™-o-methyltransferase activity. Journal of Virology,"/>
 <result pre="BaricR. S. (2014). Attenuation and restoration of severe acute respiratory" exact="syndrome" post="coronavirus mutant lacking 2â€™-o-methyltransferase activity. Journal of Virology, 88(8),"/>
 <result pre="with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1" exact="infection" post="(GS-US-380â€&quot;1490): A randomised, double-blind, multicentre, phase 3, non-inferiority trial."/>
 <result pre="(2015). Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for" exact="hepatitis C" post="in patients co-infected with HIV-1: A randomized trial. JAMA,"/>
 <result pre="from http://www.who.int/csr/sars/country/table2004_04_21/en/index.html collab: World Health Organization. (2019, November). Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) Retrieved March 28, 2020 from https://www.who.int/emergencies/mers-cov/en/"/>
 <result pre="http://www.who.int/csr/sars/country/table2004_04_21/en/index.html collab: World Health Organization. (2019, November). Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) Retrieved March 28, 2020 from https://www.who.int/emergencies/mers-cov/en/ collab:"/>
 <result pre="from https://www.who.int/emergencies/mers-cov/en/ collab: World Health Organization (2020a). Naming the coronavirus" exact="disease" post="(COVID-19) and the virus that causes it Retrieved March"/>
 <result pre="BartlamM., HilgenfeldR., &amp;amp; RaoZ. (2003). The crystal structures of severe" exact="acute" post="respiratory syndrome virus main protease and its complex with"/>
 <result pre="HilgenfeldR., &amp;amp; RaoZ. (2003). The crystal structures of severe acute" exact="respiratory" post="syndrome virus main protease and its complex with an"/>
 <result pre="&amp;amp; RaoZ. (2003). The crystal structures of severe acute respiratory" exact="syndrome" post="virus main protease and its complex with an inhibitor."/>
 <result pre="F., &amp;amp; TanW. (2020). A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. New England Journal of Medicine, 382,"/>
</results>
